◆ NeutralSRPTBNGO

Sarepta Therapeutics (SRPT) Q3 Earnings Lag Estimates

Zacks Investment Research·
Sarepta Therapeutics (SRPT) Q3 Earnings Lag Estimates

Sarepta Therapeutics (SRPT) reported quarterly earnings of $0.13 per share, missing consensus estimates of $0.37 per share, representing a -64.87% earnings surprise. While revenues of $381.35 million exceeded expectations by 9.43%, the company received a Zacks Rank #5 (Strong Sell) rating due to unfavorable estimate revisions. The stock has underperformed the S&P 500 by 24.1% year-to-date.

Read Full Article at Zacks Investment Research →
← Back to Financial Intelligence